Users will be able to access DeepScribe’s documentation platform through AWS.
DeepScribe announced that its ambient AI clinical documentation software is available as a purchasing option on Amazon’s AWS Marketplace.1 This includes the entirety of Deepscribe’s platform, including Customization Studio, Clinical Moments, and Real-Time. Healthcare organizations will have the ability to deploy ambient AI that integrates directly with their HER.
In a press release, DeepScribe co-founder and COO said, “Our inclusion in the AWS Marketplace is made possible by our work with AWS as well as the integrity of our enterprise-ready AI clinical documentation solution. The increased accessibility will enable enterprise healthcare organizations to consolidate their cloud spend and more easily deploy DeepScribe to address the critical issue of clinician burnout as it automates clinical documentation, improves efficiency, and allows greater focus on delivering patient care."
In the same press release, Deepscribe’s co-founder and CEO Akilesh Bapu said, “Healthcare systems are moving fast to adopt the AI stack of the future, from ambient AI to clinical decision support. We think it's important to make rolling out this stack as seamless as possible–with this, rolling out DeepScribe is easier than ever, directly through AWS."
In February, Deepscribe announced that it had partnered with Amazon Web Services (AWS) to develop and scale large language models for healthcare. In a press release,2 Deepscribe stated that, as part of this partnership, it would incorporate AWS HealthScribe onto its platform.
In a press release issued at the time, Covenant HealthCare vice president and chief information officer Frank Fear said, “We're extremely excited about the transformative potential DeepScribe's AI technology brings to our health system. DeepScribe is empowering us to alleviate the documentation burden, deliver exceptional patient care, and make good on our commitment to prioritize clinician well-being."
In the same press release, Bapu added, “We are excited to be working with AWS to eliminate the burden of documentation for exponentially more providers and unlock better, more accurate medical reasoning capabilities. AWS generative AI services, paired with our dataset, will allow us to push the boundaries of AI in care delivery.”
According to Deepscribe, it had already processed and labeled more than 3 million clinical conversations on the platform by February. Due to the nature of these conversations, they were de-identified prior to being processed. This data was used to train multiple LLMs and AI programs to be used within the healthcare landscape.
AWS’ chief medical officer, Jared Saul, said in a press release, “Reducing documentation burden is a prime example of how generative AI can be applied to positively impact clinician and patient experiences. We're excited to be supporting DeepScribe's work in scaling adoption of clinical AI and purpose-built LLMs."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.